
    
      The study will consist of 3 treatment arms, each consisting of approximately 100 subjects.

      Treatment Arm 1 will receive 1g Oral DS107 daily. Treatment Arm 2 will receive 2g Oral DS107
      daily. Treatment Arm 3 will receive placebo daily.

      The primary objective of the study is to assess the efficacy and safety of daily 1g and 2g
      doses of Oral DS107 versus placebo.

      Subjects will come to the clinic on 7 occasions: Screening, Baseline, Week 2, Week 4, Week 6,
      Week 8 (end of treatment/early termination) and Week 10 (follow-up). The primary efficacy
      variable will be the IGA (Investigator's Global Assessment). Secondary efficacy variables
      will include IGA, EASI (Eczema Area and Severity Index), and NRS (Numeric Rating Scale),
    
  